Springer, Magazine of European Medical Oncology, 1(13), p. 32-35, 2020
DOI: 10.1007/s12254-019-00558-z
Lippincott, Williams & Wilkins, HemaSphere, 2(3), p. e185, 2019
DOI: 10.1097/hs9.0000000000000185
Full text: Download
SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30–40% of non-Hodgkin’s lymphoma. Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. Currently, therapy with autologous chimeric antigen receptor T‑cells (CAR T‑cells) provide encouraging complete responses (CR) of up to 50%. However, high costs for approved products and elaborate logistics have to be encountered.